The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Vertex Pharma could be close to succeeding in ... arm safety and effectiveness study of the drug in various surgical and non-surgical pain settings. Treatment with the drug was associated with ...
In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated statistically significant reductions in acute surgical pain over 48 hours ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results